IP licensing and business: Oct. 23-Nov. 5
Drugmakers secured experimental treatments, expanded biosimilar portfolios and renegotiated royalty obligations, while life-sciences companies acquired technology and resolved patent disputes. Elsewhere, licensing provided access to solar power technology and computing patents,...To view the full article, register now.
Already a subscriber? Click here to view full article